Nevertheless, subsequent meta-analyses and randomized controlled clinical trials did not find an association between GLP-1 receptor agonists and an increased risk of the above cancers (Ryder, 2013; Monami et al., 2017; Cao et al., 2019). The gene discussed is GLP1R; the disease is cancer.